BioSpace News Archive

Moleculin Biotech, Inc announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company’s ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).

Myomo, Inc. announced that the Centers for Medicare & Medicaid Services posted a proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rate for the MyoPro® to be discussed at CMS’ bi-annual Healthcare Common Procedure Coding System Public Meeting, scheduled for November 29, 2023.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics.

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300.

Lerna Biopharma Pte. Ltd proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting in Boston organized by American Association for the Study of Liver Diseases from November 10th to 14th.

Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer’s disease dementia.

Nexcella, Inc. today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Shattuck Labs, Inc. today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023.